Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK), dated April 16, 2009, announces a strategic agreement with Pfizer Inc. to create a new, independent, world-leading specialist HIV company. The transaction combines the HIV portfolios of both firms to focus exclusively on the research, development, and commercialization of HIV medicines. The new entity is expected to close in the fourth quarter of 2009, subject to regulatory and tax clearances.
Key Financial Metrics and Transaction Structure
- Equity Split: GSK will initially hold an 85% equity interest, while Pfizer will hold 15%.
- Pro-Forma Revenue (2008): The combined portfolio of 11 marketed products generated approximately £1.6 billion in sales.
- Pro-Forma Operating Profit (2008): Approximately £870 million.
- Asset Valuation: The book value of gross assets contributed by both companies is approximately £250 million.
- Accounting Impact: GSK will record a one-off non-cash, pre-tax accounting gain in Q4 2009 upon closing, classified within other operating income.
- Cost Savings: The transaction is expected to realize annual pre-tax cost savings of up to £60 million by 2011.
Material Changes and Financial Outlook
The transaction represents a material strategic shift for GSK, consolidating its HIV business into a fully consolidated subsidiary. While the filing does not provide full-year 2009 financial results for GSK, it outlines specific impacts on earnings and cash flow:
- Earnings Per Share (EPS): GSK anticipates marginal near-term EPS dilution of approximately 1% to 2% in 2010 and 1% in 2011. This dilution is expected to reverse as the new company's pipeline generates sales.
- Cash Flow: GSK expects a small adverse impact on reported cash flow in 2010-2011 due to minority dividends paid to Pfizer, with cash flow becoming accretive by 2012.
- Pfizer Impact: The transaction is expected to be neutral to Pfizer's earnings in 2009 and slightly accretive in 2010 and 2011.
- Equity Adjustment: The initial 85/15 split is subject to adjustment based on sales and regulatory milestones. If all milestones are met, the split would shift to 75.5% (GSK) and 24.5% (Pfizer).
Guidance, Risks, and Contingencies
Management commentary emphasizes that the new company will hold a 19% share of the growing HIV market and possess an industry-leading pipeline of 6 innovative medicines, including 4 in Phase II development. The new entity will contract R&D services from both parent companies and benefit from a Research Alliance Agreement granting exclusive rights of first negotiation on new HIV medicines developed by GSK or Pfizer.
Risks and Contingencies:
- Closing Conditions: The transaction is conditional on regulatory and tax clearances and the absence of a material adverse change in either company's HIV business prior to closing.
- Forward-Looking Statements: Both companies caution that projections regarding revenues, pipeline success, and financial impacts are subject to substantial risks, including regulatory approval uncertainties and competitive developments.
- Operational Risks: Success depends on the integration of commercial infrastructure and the ability to deliver cost savings.
Key Facts for Investor Verification
- Verify the final closing date of the transaction, currently targeted for Q4 2009.
- Monitor the realization of the one-off non-cash accounting gain in GSK's Q4 2009 financial statements.
- Track the achievement of sales and regulatory milestones that could alter the equity split between GSK and Pfizer.
- Assess the actual EPS dilution for GSK in 2010 and 2011 against the projected 1-2% range.
- Confirm the progress of the 17 molecules in the combined pipeline, particularly the 4 compounds in Phase II development.